Recent Updates

Added three companies to the Pipeline Watchlist: Otovia Therapeutics, EmayGene, and Salubritas Therapeutics, all working on hair cell regeneration / OTOF gene therapy for hearing loss (not tinnitus-specific), flagged as ones to watch for a first-in-human regeneration trial.

Launched a new AI Frontier page tracking general-purpose AI initiatives in biology, drug discovery, and genomics (Isomorphic Labs, AlphaFold, AlphaGenome Atlas, Xaira Therapeutics, Chai Discovery, Insilico Medicine, Evo 2, Nvidia BioNeMo, GPT-Rosalind). None have a hearing loss or tinnitus program today; tracked as infrastructure that could one day accelerate treatment research.

New paper: a serotonergic dorsal raphe → dorsal cochlear nucleus circuit drives fusiform-cell hyperactivity and tinnitus-like behavior in mice, reversible by blocking 5-HT2A receptors (Yu, Dai, ..., Tang, Trussell, PNAS). Linked to Dorsal Cochlear Nucleus Origin.

New paper: sex-adjusted ABR Wave I amplitude norms flag likely cochlear deafferentation in living patients, catching 51% of a high-risk veteran sample (Kampel, Bramhall et al., American Journal of Audiology). Linked to Cochlear Synaptopathy.

Confirmed NCT07648615 is a separate, unrelated European program (ENTIC), not the same device as TINIS.

Added to Clinical Trials: NCT03988699 (Mayo Clinic 'Novel Tinnitus Implant System' feasibility study), now Completed, no results posted yet.

NCT07777549 updated (Aug 20, 2026) with estimated primary completion Aug 2027; still not yet recruiting.

Biohaven out-licensed opakalim and its Kv7 platform to SK Biopharmaceuticals for up to $795M plus royalties; still epilepsy-only, no tinnitus relevance. Note: puts Biohaven behind XEN1101 (Xenon targeting Q3 2026 NDA) while opakalim awaits RISE3 results.

NCT07777549 (A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B)): phase: Phase 2a → Phase 2.

Registered Phase 2a trial found for TRTL-913 (NCT07777549): a 7-day double-blind safety/PK study in healthy volunteers plus a 14-day open-label efficacy study in adults with chronic tinnitus, measuring TFI, THI, and loudness/annoyance VAS. Not yet recruiting, estimated start Sep 2026, site in Auckland, NZ.

New paper: blood RNA-seq and a mouse model share the same inflammatory signature, and blocking TNF-alpha/microglia reduces tinnitus-like behavior in mice (Cheng et al., Neuroscience Bulletin). Linked to Central Neuroinflammation.

New paper: human EEG study finds distinct brain-network signatures for acute vs. chronic tinnitus (Gong et al., iScience). Linked to Interacting Brain Networks.

New paper: national VA cohort of 267,395 veterans finds tinnitus in 47%, more common with TBI, anxiety, or depression (Clifford et al., Ear and Hearing).

New paper: synaptic zinc plasticity in auditory cortex explains both adaptive recovery and maladaptive hyperactivity after cochlear injury (Kumar et al., Science Advances). Linked to Central Gain and PV Interneuron Dysfunction.

Added Cilcare's planned CIL001 interventional program: three Phase 1b/2a studies (type 2 diabetes, chronic tinnitus, mild cognitive impairment) and their target start dates.

CIL001 entry revised to align strictly with details from Cilcare's TinnitusTalk podcast appearance, trial design, timelines, and the DIAMONT/SAFIER observational studies that shaped it.

Added NEU-002 (NeuDirection) to the pipeline and knowledge base, plus sponsor company entries linking treatments to the companies developing them.